Bookmark
Forward
Explore Literature Results
Explore Clinical Trials Results
QuickView for hemophilia without inhibitors
Most Relevant Literature
- Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemop…
- Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients wit…
- Management of bleeding events and invasive procedures in patients with haemophilia A without inhibit…
- A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibit…
- A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemo…
Most Relevant Clinical Trials
- The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Par…
- Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergo…
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emi…
